CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2019– Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported updated, preliminary primary and secondary endpoint data from the Company’s Phase 3 VISTA trial further supporting the strong benefit-risk profile of Viciniumfor the potential treatment of patients with high-risk,bacillus Calmette-Guérin …